ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-sale
ACADIA PHARMACEUTICALS INC. (ACAD) had Debt Securities, Available-for-sale of $260.63 million as of 2014-12-31, per its 10-K filed 2015-02-26.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2015-02-26
- 2014-12-31: Debt Securities, Available-for-sale $260.63M.
- 2014-09-30: Debt Securities, Available-for-sale $301.43M.
- 2014-06-30: Debt Securities, Available-for-sale $340.75M.
- 2013-12-31: Debt Securities, Available-for-sale $174.08M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2014-12-31 | $260.63M 10-K · filed 2015-02-26 |
| 2014-09-30 | $301.43M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $340.75M 10-Q · filed 2014-08-05 |
| 2013-12-31 | $174.08M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |